



Melding Physics and Biology: Two Novel Concepts

Presented to
The Physics Division Review Committee
(5-6 February 2001)

Robert H. Kraus, Jr., Ph.D. (PI)
Biophysics Group, P-21
Los Alamos National Laboratory



Outline

Two new directions

using magnetic micro/nano particles and SQUID sensors to solve important biological problems.

- *'Molecular imaging' and 'Magnetocarcinotherapy' – imaging and therapy with magnetic nanoparticles.*
- *Massively parallel bioassay with magnetic markers*

Background & Relevant Technology

Basic Concepts

Results to date

Current Status & Near-Term Plans



Our Collaborators

*University of Nebraska, Lincoln
University of Nebraska, Omaha Medical Center
University of New Mexico*

B-Division (LANL) – J. Nolan, R. Atcher, et al.

C-Division (LANL) – D. Berning

SNS-Division (LANL) – W. Reass, et al.

Funding

LANL LDRD; P-Division



Background & Introduction

Molecular targeting of magnetic nanoparticles for imaging & therapy

- *Uses the targeting technologies developed in BNCT, Scintigraphy, etc.*
- *Combine magnetic nanoparticles with appropriate targeting molecule (antibody, protein, DNA sequence, etc.)*
- *'Image' localized concentrations of magnetically labeled cells in vivo using MEG (SQUID array) technology.*
- *Energy transfer mechanism to magnetic domains results in therapeutic effect with minimal collateral damage.*

Detection Concept

Targeting

Selectively bind *magnetic nanoparticles* to tumor cells

Generally, bind *magnetic nanoparticles* to cell receptors, enabling localization of cell types by the molecular (target-receptor) interactions.


Detection

SQUID Sensor technology used to detect localized concentrations of magnetic nanoparticles.


Imaging

Use functional brain imaging methods to 'image' localized concentrations of magnetic nanoparticles. (A method to obtain tomo-

R.H. Kraus, Jr., Ph.D. rkraus@lanl.gov Biophysics Group, Los Alamos National Laboratory



Magnetic nanoparticle technology




Methods to sort by particle size developed.


Process to produce material with uniform size distribution under development (UNL)

Method to encapsulate particles or groups of particles available (LANL, UNMC, industry)


Instrumentation



Modeling & Computation



Visualization



Localizing
concentrations of magnetic particles *in vivo* uses techniques developed for functional brain mapping

Concept to obtain true tomographic images currently being reviewed for patent.

Particle/Field Requirements to 'Image'

Nanoparticles (10nm radius)	N particles	Field @ 5cm	particles/cell*	grams
L + n(Fe ₂ O ₃)	~3. x 10 ⁶	1pT	~1	2. x10 ⁻¹¹
L + n(SmCo ₅)	<10 ⁶	1pT	~1	~3 x10 ⁻¹¹
nanoparticles (100nm radius)	N particles	Field @ 5cm		grams
L + n(Fe ₂ O ₃)	2.4x10 ³	1pT	~10 ⁻³	7.8x10 ⁻¹¹
L + n(SmCo ₅)	~10	1pT	~10 ⁻⁵	3.3x10 ⁻¹³

* Assumes 1mm³ tumor

L = Targeting agent (e.g. monoclonal antibody as per:
del Gratta, et al., Phys. Med. Bio. v40, p671-681 (1995))
Remnant magnetization: (Fe₂O₃) <10G (7-9 typical)
(SmCo₅) >10,000G (11,000-12,000 typical)

Magnetoencephalography practical detection limit ~10fT

Mechanisms of Thermal Deposition (Basic concepts)

Target: >25°C rapid temperature increase in <<1 min.

Cell necrosis instantaneous at 25°C above body norm.

Onset of cell necrosis 6-10°C above body norm – collateral damage.

Minimize collateral damage due to thermal diffusion.

$$\dot{Q}_{\text{visc}} \sim 8\eta a^3 \chi B_o M \quad \dot{Q}_{\text{hyst}} \sim a^3 \chi B_o^2; \quad \dot{Q}_{\text{ohmic}} \sim R(\chi B_o)^2$$

B_o = external applied field ~ 1kG

M = particle magnetization > 10kG

R = tissue resistivity; a = particle radius; χ = viscosity.

Balance heating in tumor against global tissue heating and thermal diffusion.

Treatment Approach



Thermal Energy Deposition – Rapid & Significant

Use ‘shaped’ RF magnetic field coupled to “supermagnets” to induce thermal energy deposition (*distinct* from traditional hyperthermia using magnetic materials)

Tumor necrosis, Collateral Damage

- $>25^{\circ}\text{C}$ (45°F) temperature rise is *immediately* necrotic to cells
- Rapid thermal deposition minimizes thermal diffusion & associated collateral damage
- phagocytosis removes necrotic tissue over time obviating surgery

Therapy array concept & 1st generation hardware







Phase-coupled
power supply
and test magnet

Capable of
1.8-3MHz
>10kW power



Modeling the temporal evolution of thermal energy deposition.
Assume: ~1 nanoparticle/cell
Populate only outer layers of tumor



Modeled thermal energy deposition into tissue using the following assumptions:

- Viscosity = ~water
- Conductivity = 0.5% saline
- Global $\Delta T = 3$ degrees
- Uniform field globally applied
- Spherical nanoparticles
- No "spin-up" needed

* Rotational energy \gg covalent bond energy

MCT Status

- Broad patent allowed
- Magnetic material technology in hand
 - nanoparticle SmCo
- Detection method & 'imaging' methods in hand
 - SQUID array and source localization codes at LANL
 - True tomographic imaging approach conceived recently
- RF PS and magnet in fabrication
 - complete ~March 2002
- Thermal imaging experimental hardware in hand
- Target-binding chemistry options developed
 - Atcher, et al. at LANL

MCT Program Development


- Significant interest generated at NIH (NCI, NIBIB)
- Encouraging feedback from DOE/OBER
- Recent interest generated with P&G
- Molecular imaging LDRD/DR and NASA/NCI "Program-Project" grant (Swanson, et al.)
- NIH Grants in preparation – NCI, NIBIB institutes targeted; BRP funding mechanism suggested.

Bioassay with Magnetic Nanoparticles

Collaborators


J. Nolen, et al. – LANL NIH Flow Resource
(Builds on existing world-leading expertise in Flow Resource)
D. Leslie-Pelecky, et al. – U. Nebraska, Lincoln

Funding
LANL LDRD



Novel Bioassay Technique - LDRD:

- Perform bioassay measurements with large number of agents simultaneously (massively parallel).
- Magnetic particles are used to “label” different assay agents (magnetic moment).
- Assay “bins” are separated ...
 - By measuring the magnetic moment directly
 - Use a spectrometer-like apparatus
- $\sim 10^3$ and 10^4 separable bins are envisioned for range of 100nm to 5 μ m magnetic particles. First generation system will target $\sim 10^2$




Magnetic beads enable ...

- **Avoiding the need for ‘a priori’ stringent QC in bead preparation**
- **Parallel separation and collection of agents**
 - prepare protein samples for crystallography
 - preparation of specifically identified DNA fragments
 - collection of antibodies for variety of receptors
 - etc.

Through application of a ‘fluid spectrometer’



Bioassay Magnetic bead separation



The magnetic bead spectrometer can readily be coupled to laser fluorescence detection (to monitor chemistry) at flow inlet or any (or all) of the particle collection channels.

Bioassay Status:

- Flow system complete.
- Particles encapsulated (in variety of polymers).
- Particles detected with SQUID (High-T_c Jena array SQUID).
- SQUID dewar in fabrication.
- First generation spectrometer flow chamber fabricated.



Near term:

- Magnetic moment S/N and error study
- Coincident chemical (laser fluorescent) interrogation with SQUID

Future:

- NIH Grant proposal in conjunction with LANL Flow Resource
- Commercialization (contacts being investigated, CBD ad placed.)